TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01682928
Drug: IV/Oral Hydration and Bedrest
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Maternal BP (sitting)~* Pulse Pressure~* Pulse~* Urine Specific Gravity BID~* Fetal Heart Rate~* Maternal Body Weight US Procedures~* AC/EFW~* Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~* Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~* AFI (Baseline, day 3, 7 {or Discharge})~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~* 1 Liter Water PO over 2 hours~* 1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\\hr for duration of the study participation~* Strict I/O's~* Vital signs
Study: NCT02402270
Drug: NuLYTELY® (PEG 3350)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02402270
Drug: ECP-019
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02402270
Drug: MoviPrep® (PEG 3350)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00561470
Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The FOLFIRI regimen was initiated immediately after Placebo administration on Day 1~The FOLFIRI regimen included:~* 180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:~* 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:~* 5-FU 2400 mg/m² continuous IV infusion over 46-hours
Study: NCT00561470
Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The FOLFIRI regimen was initiated immediately after Aflibercept administration on Day 1~The FOLFIRI regimen included:~* 180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:~* 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:~* 5-FU 2400 mg/m² continuous IV infusion over 46-hours
Study: NCT03256292
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement therapy
Study: NCT00725101
Drug: Treatment for Fibromyalgia
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FM participants starting any new pharmacologic FM agent.
Study: NCT03485911
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching oral capsules administered once daily
Study: NCT01819857
Drug: Xomolix 0.625 mg intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous administration of 0.625 mg droperidol
Study: NCT03597035
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study participants will receive concomitant treatment with Veltassa 8.4 grams per day and Spironolactone 25 mg per day or maximum tolerated dose. If dictated by the potassium level, Veltassa can be increased to 16.8 grams per day.
Study: NCT02558543
Drug: Ringer lactate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002615
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01581320
Drug: Test group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a month, administration of DP-R206 \& placebo for 16 weeks
Study: NCT01581320
Drug: Reference group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a month, administration of Bonviva \& placebo for 16 weeks
Study: NCT00398437
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00825656
Drug: Sinol or Sinol-M nasal spray
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: One spray in each nostril up to a maximum of 12 times / day on an as needed basis
Study: NCT00100841
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00100841
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02920177
Drug: Kenalog 10 MG/ML Injectable Suspension
Normalized name: Kenalog 10 MG/ML Injectable Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL corticosteroid injection
Study: NCT00003340
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00105287
Drug: OraVescent fentanyl (OVF)
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00145301
Drug: Lumiracoxib
Normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02134353
Drug: Placebo Comparator: Arm B - Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator: Arm B - Control BD for 26 weeks
Study: NCT02204202
Drug: [18F]FDG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 millicuries (mCi) of \[18F\]FDG will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
Study: NCT04347005
Drug: Cohort 1: AR882
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of AR882 or matching placebo
Study: NCT04347005
Drug: Cohort 2: AR882
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of AR882 or matching placebo
Study: NCT04347005
Drug: Cohort 3: AR882
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of AR882 or matching placebo
Study: NCT04347005
Drug: Cohort 4: AR882
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of AR882 or matching placebo
Study: NCT04347005
Drug: Cohort 5: AR882
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of AR882 or matching placebo
Study: NCT04347005
Drug: Cohort 6: AR882 Food Effect
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of AR882 or matching placebo in a fed state
Study: NCT04347005
Drug: Cohort 7: AR882 Solid Oral Formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of AR882 or matching placebo
Study: NCT01381549
Drug: GSK2251052
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
Study: NCT00574210
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablets administered twice per day
Study: NCT04510493
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqua ad injectabilia in 250 ml 5% dextrose solution i.v. over 2 hours
Study: NCT00824057
Drug: AZD6280
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00256321
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000mg/m2 PO BID from Days 1 through 14.
Study: NCT00256321
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 400mg PO BID from Days 1 through 21.
Study: NCT00824057
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT04221321
Drug: RAPA114
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAPA114 tablet
Study: NCT00996164
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will be randomized to flibanserin or placebo in a double-blind manner
Study: NCT01482091
Drug: Fentanyl Citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single dose of fentanyl citrate (2 mcg/kg; max 100mcg) administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device
Study: NCT01482091
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of equivalent volume of 0.9% Normal Saline will be administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device.
Study: NCT01101659
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT01101659
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT00221286
Drug: pegIFN / TDF / FTC combination therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03723343
Drug: GP+IMRT
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m2 intravenously, d1\&d8 +Cisplatin 80 mg/m2 intravenously, d1 21\~28 days/cycle, 4 patients with oligometastasis, 6 cycles with multiple metastases
Study: NCT03723343
Drug: TPF+IMRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel: 75mg/m2 intravenous drip, d1+Cisplatin75mg/m2 intravenous drip, d1\~d5+5-fluorouracil 750mg/m2/d intravenous drip, d1\~d521\~28 days/cycle, patients with oligometastasis take 4 cycles, moreTransfer patients for 6 cycles
Study: NCT00028600
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4g/sq m IV infusion over 1-2 hrs D 1 for auto, and 1g/sq m/d IV infusion over 1 hr on D -4 thru -3 for allo, transplant prep
Study: NCT00028600
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5mg/sq m/d IV infusion D 1,3,\& 6: allo transpl
Study: NCT02410083
Drug: Clopirin 1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02410083
Drug: Clopirin 2
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01729767
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who are randomly placed in placebo group, besides sticking with low salt diet will take the placebo (inert ingredient) for 10 days 5 times a day, then 3 times a day for next 10 days, and 2 times a day for the last 10 days. Patients would receive the medication in 2 sessions, first in the beginning of the study and the rest after 10 days. This way it would boost their compliance, and physicians would be aware of possible complications. Patients will report changes in their symptoms 10 days after initiating the drug and in 1, 3, and 6 month intervals. All changes in frequency and duration of vertigo attacks are recorded, and tinnitus and aural fullness is recorded in a 0(with no symptom) to 4 (very severe) scale.
Study: NCT04378023
Drug: Neoadjuvant Chemo-radiotherapy
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive neoadjuvant radiotherapy (External - 50-54 grays) following by concomitant oral capecitabine (825mg/m2 bid).Thereafter, gemcitabine iv (1000mg/m2) plus cisplatin iv (25mg/m2) will be administered the day 1 and 8 every 21 days until transplant.
Study: NCT02628392
Drug: DS-8500a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-8500a tablets 25mg, 50mg, 75mg
Study: NCT02628392
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching DS-8500a tablets and sitagliptin capsules
Study: NCT02206022
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pain's evaluation for Remifentanil Group
Study: NCT02206022
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVC pain's evaluation after local anesthesia + placebo infusion
Study: NCT04184349
Drug: LA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the LA group, only the local anesthetic infiltration will be performed by injecting the numbing medicine ropivacaine into the surgical site.
Study: NCT04184349
Drug: B Group
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the B Group,pectoral (PECS) and transversus thoracic plane(TTP) blocks will be performed by injecting the numbing medicine ropivacaine near the nerves.
Study: NCT00322127
Drug: AMD3100
Approvals — FDA: no, EMA: no, PMDA: no
Description: a 2 mL clear glass vial containing 1.7 mL of a sterile isotonic solution.
Study: NCT02908074
Drug: BGS649
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules will be taken weekly for a maximum of 24 weeks
Study: NCT02978391
Drug: epinephrine endoscopic injection (conventional therapy)
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: endoscopic submucosal injection of epinephrine (1: 10,000)
Study: NCT03880981
Drug: Ibuprofen 600 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen 600mg Po q 6 hours prn pain
Study: NCT03880981
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetaminophen 600mg po q6 hours prn pain
Study: NCT02948309
Drug: Mistletoe extract (Iscador Qu)
Normalized name: MISTLETOE EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1ml subcutaneous injection 3 times/week, dose escalation 0,01mg - 20mg
Study: NCT02948309
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1ml subcutaneous injection 3 times/week
Study: NCT02889666
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular placebo in replacement of agent-specific chemotherapy was supplied to these patients.
Study: NCT02663297
Drug: ATLCAR.CD30 cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three dose levels will be evaluated:~Group One, 2x10\^7 cells/m\^2 (maximum dose 5x10\^7 cells)~Group Two, 1x10\^8 cells/m\^2 (maximum dose 2.5x10\^8 cells)~Group Three, 2x10\^8 cells/m\^2 (maximum dose 5x10\^8 cells)
Study: NCT00493233
Drug: 2 antipsychotic medications (combinations of olanzapine, risperidone, clozapine, seroquel, haldol, perphenazine)
Normalized name: ANTIPSYCHOTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary antipsychotic medication (olanzapine, oral risperidone, seroquel, clozapine, haldol, perphenazine) will be determined by the treating physician and participants will continue taking the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician. The dose of the second antipsychotic drug will remain fixed throughout the study period.
Study: NCT00493233
Drug: main antipsychotic medication and placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The main antipsychotic drug will be determined by the treating physician. Participants will be allocated to placebo in place of the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician.
Study: NCT04734548
Drug: ApTOLL
Approvals — FDA: no, EMA: no, PMDA: no
Description: ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatory response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.
Study: NCT01764997
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dispensed according to local practice.
Study: NCT01764997
Drug: Placebo (for sarilumab)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01265901
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One single low-dose i.v. infusion prior to the first vaccination
Study: NCT02201056
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-935 placebo-matching oral solution
Study: NCT03424629
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will be administered Methotrexate (each time 5-25mg) orally once a week for successive 16 weeks(week 0-15).
Study: NCT04221165
Drug: Opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioids will be prescribed as per institutional standards.
Study: NCT01039909
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight size 00 Swedish orange opaque hard gelatin capsules containing placebo are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
Study: NCT04015518
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of placebo matching Spesolimab from week 0 to 16.
Study: NCT01085136
Drug: Investigator´s choice of chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBW 2992 in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
Study: NCT01085136
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBW 2992 will be given in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
Study: NCT00953303
Drug: glucocorticoid
Normalized name: Glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of Dexamethasone (20mg/day) followed by prednisone 1mg/kg/day with a maximum dose of 60mg/day.
Study: NCT00953303
Drug: standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will be given standard care such as diuretics, inotropic and/or vasodilator in acute decompensated congestive heart failure management.
Study: NCT01039909
Drug: SRT2104
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
Study: NCT03718390
Drug: Formulation A
Normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation A (37/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
Study: NCT03718390
Drug: Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation B (46/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
Study: NCT03718390
Drug: Formulation D
Normalized name: Complete Formulation D3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation D (46/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
Study: NCT04986241
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic use of statin prescribed previously by the assistant physician.
Study: NCT00503451
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03525028
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigators use placebo in the control group.
Study: NCT02759185
Drug: THC/CBD cannabis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three weeks of smoking cannabis containing equal amounts of THC and CBD with smoking limited to no more than 1.8 g per day.
Study: NCT01199926
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (microcrystalline cellulose) ingestion each day for 12 weeks.
Study: NCT03163576
Drug: Phosphate Binder
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT00004062
Drug: liothyronine sodium
Normalized name: Liothyronine Sodium
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02134002
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thirty cocaine dependant patients will be included in this study during their hospitalization for withdrawal. After the inclusion visit, they will be randomized to receive disulfiram 250 mg/day or placebo over the 15 days of their hospitalization.
Study: NCT02134002
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thirty cocaine dependant patients will be included in this study during their hospitalization for withdrawal. After the inclusion visit, they will be randomized to receive disulfiram 250 mg/day or placebo over the 15 days of their hospitalization.
Study: NCT04355806
Drug: PD-1/PD-L1 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Including nivolumab, pembrolizumab, atezolizumab, and durvalumab, et al.
Study: NCT02428374
Drug: Rosuvastatin plus clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crestor 40 mg daily plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo
Study: NCT02428374
Drug: Rosuvastatin plus ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crestor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo
Study: NCT02428374
Drug: Simvastatin plus clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zocor 40 mg plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo
Study: NCT02428374
Drug: Simvastatin plus ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zocor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo
Study: NCT03919500
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants in control group are administered normal saline with the same volume and period as EPO.
Study: NCT01573767
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation powder during treatment period
Study: NCT00775814
Drug: Candesartan and Hydrochlorothiazide
Normalized name: Candesartan and hydrochlorothiazide only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for 2 weeks; increased to Candesartan 16 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.
Study: NCT01009021
Drug: potassium diclofenac
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: potassium diclofenac 50 mg, one tablet 45 minutes before laser treatment
Study: NCT01400139
Drug: Hydrocodone bitartrate q24h film-coated tablets
Normalized name: hydrocodone
DrugBank: Hydrocodone (DB00956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocodone bitartrate q24h film-coated tablets 20 - 120 mg once daily
Study: NCT04713436
Drug: Differentiation Markers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteocalcin (BGLAP), dentin sialo phosphoprotein (DSPP) and alkaline phosphatase (ALPP) gene expression levels were also evaluated.